Oasis Fertility, a specialty healthcare firm, has announced a $50 million investment from Kedaara Capital. The private equity firm will help the startup make strategic inroads in the existing market.
“Oasis has established a scalable, reproducible platform and supports a distinct culture with clinical quality and ethics at its center,” stated Nishant Sharma, Kedaara Capital’s CIO and Managing Partner.
According to the business’s announcement, Kedaara Funds purchased a major minority investment in the company for $50 million, with a commitment to deploy more capital for strategic acquisitions and assist Oasis in becoming the leading fertility chain in India and adjacent regions. InvAscent, which invested in the company in 2016, will also benefit from the purchase.
The funds will be used to grow the company’s brand presence throughout India and to add support workers to meet the increased demand for specialty healthcare-based services.
“We are happy to be using Kedaara’s experience of the sector and the Indian market,” said Kiran Gadela, Co-founder and Managing Director of Oasis Fertility. We are excited about this collaboration as we embark on a path to pursue potential synergistic acquisitions and build a top fertility platform in India and South Asia to promote our core mission of assisting couples in becoming parents.”
Dr. Durga G. Rao and Kiran Gadela founded the Hyderabad-based firm in 2009, and it has since expanded to a network of 26 clinics in 16 locations, more than doubling its income in the previous three years. AndroLife, a first-of-its-kind andrology (male infertility) practice, was just launched by Oasis. The transaction’s only financial advisor was O3 Capital. Oasis, InvAscent, and Kedaara Capital were represented by legal counsel from Samvad Partners, Quillon Partners, and Veritas Legal.
